<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical application of resistance reversal drugs for patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> is reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>The phenomenon of multidrug resistance versus other mechanisms are discussed </plain></SENT>
<SENT sid="2" pm="."><plain>The pump-like mechanisms of P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, multidrug resistance associated protein, lung resistance protein and of other ATP binding cassette transporter proteins are reviewed briefly, as well as the important substrate drugs and pump-blocking compounds </plain></SENT>
<SENT sid="3" pm="."><plain>The problems associated with resistance protein assays in clinical samples and the concept of prognostic versus therapeutic clinical relevance are described, within the context of selected <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicities and treatment outcomes of phase II and III trials of reversal agents in <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e> of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> are reviewed </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, current options for on-study management of relapsed or <z:e sem="disease" ids="C1335724" disease_type="Neoplastic Process" abbrv="">refractory hematologic malignancy</z:e> patients are discussed </plain></SENT>
</text></document>